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Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of thyroid cancers are anaplastic, but
the disease contributes to 14–50% of the mortality with a median survival of 3 to 5 months. Most patients diagnosed with this
disease are 65 years of age or older. The incidence of anaplastic thyroid cancer is decreasing worldwide. Most patients present
with a rapidly growing neck mass, dysphagia, or voice change. We performed a comprehensive literature search using PubMed
focusingonthe treatment ofanaplasticthyroid cancer includinghistoricalreview oftreatment andoutcomes andinvestigations of
new agents and approaches. A total of sixteen chart review and retrospective studies and eleven prospective studies and/or clinical
trials were reviewed. The current standard therapeutic approach is to consider the disease as systemic at time of diagnosis and
pursue combined modality therapy incorporating cytoreductive surgical resection where feasible and/or chemoradiation either
concurrently or sequentially. Doxorubicin is the most commonly used agent, with a response rate of 22%. Several new agents are
currently under investigation. Referral of patients for participation in clinical trials is needed.
1.Introduction
Anaplastic thyroidcancer(ATC)isoneofthemost aggressive
solid tumors to aﬀect humans, with a median survival on
the order of 3 to 5 months following diagnosis [1–25]. One-
year and 10-year survival rates are estimated at 10–20% and
less than 5%, respectively, though some reports question
the reliability of diagnoses in these long-term survivors
[11, 26, 27]. Even though less than 1–3% of all thyroid
cancers are anaplastic tumors, it contributes up to 14–50%
of the annual mortality associated with thyroid cancer [8,
11, 28]. Recent advances in understanding the genetic and
molecular pathogenesis of ATC hold promise for targeted
therapy for this disease. ATC is usually resistant to standard
chemotherapy.There areseveralclinicaltrialsunderwaywith
small molecule tyrosine kinase inhibitors, antiangiogenesis
agents and vascular-disrupting agents which might oﬀer
more drugs in the therapeutic armamentarium to combat
this disease.
2.ClinicalExperiencesat OurInstitution
We identiﬁed all the cases of ATC from 1987 to 2007 at the
Mary Babb Randolph Cancer Center, Morgantown, WVa,
USA. Appropriate IRB approval was obtained. Data was col-
lected on demographics, grade, stage, and diﬀerent modali-
ties of treatment and survival. SPSS was used to analyze the
demographic and survival data.
A total of 11 cases were identiﬁed at our cancer center
from 1987 to 2007. Out of these patients, 7 (64%) were
female and 4 (36%) were male (P<. 001). The average2 Journal of Oncology
age of diagnosis was 69 years. The average age was 70
years among female and 67 years among male patients.
All of these patients were white and had grade IV disease
(100%) at diagnosis. Eight (73%) patients had stage IV
diseases at the time of diagnosis, and only three patients
(one from each stage) had stage I to III diseases at the time
of diagnosis. Most patients received combination therapy
that consisted of surgery and radiation. Eight (73%) had
surgery, eight (73%) patients received radiation therapy, and
only 5 (45%) patients received chemotherapy. Patients with
stage IV diseases at diagnosis, who received surgery followed
by radiation therapy, had signiﬁcantly longer survival than
the patients with stage 4 diseases at diagnosis who received
surgery after chemotherapy or radiation therapy (44 months
versus 9 months, P<. 0001). The patients who received
surgery had signiﬁcantly better survival than the patients
who did not receive surgery (P<. 001). In our cohort of
11 patients, multimodality treatment consisting of surgery
in combination with either radiation or chemotherapy had
better outcomes than any of these treatments alone.
3.Incidence
ATC is primarily a disease of the elderly. In one American
and German prospective study of 5,583 cases of thyroid
carcinoma, 67% of patients who had ATC were over 70 years
of age. In the same study, females constituted 70% and males
30% of ATC patients [7].
Based on epidemiological studies derived from the
Surveillance, Epidemiology and End Results (SEER) data-
base, the incidence of ATC has held steady in the United
States during the period between 1973 and 2002 [29]. The
incidence of ATC is estimated at 1 to 2 cases per million
population per year, and the trend has been decreasing even
though the incidence of well-diﬀerentiated subtypes (e.g.,
papillaryandfollicular)ofthyroidcancerhasbeenincreasing
[29]. In a retrospective cohort analysis done by Davies and
colleagues using the SEER database, there were roughly
24,000 new cases of thyroid cancer in 2002 of which ATC
constituted 2% [29]. A study done in Rochester, Minnesota
found that the age-adjusted incidence of ATC was 0.1 per
100,000 person/year (95% Conﬁdence Interval (CI) 0.0–0.3)
[2]. From 1973 to 2002, there was a 2.4-fold increase in all
thyroid cancer with no signiﬁcant change in the incidence
of ATC. Papillary thyroid cancer, which increased from 2.7
to 7.7 per 100,000, contributed to almost all of the increase.
It should be noted that cancers less than one centimeter
accounted for 49% and tumors less than two centimeter
accountedfor87%oftheincreaseintheperiodbetween1988
and 2002. There was no change in the mortality associated
with thyroid cancer during the same period. This raises the
question whether early diagnosis was leading to unnecessary
interventions.
Studies published from Italy showed a reduction of ATC
from 4% to 1% between 1969 and 1973, while another
study in India showed a decline from 8% to 4% between
1989 and 1993 [42–44]. Although well-diﬀerentiated thyroid
cancer has increased in Japan, the incidence of ATC has
remained stable [45, 46]. In Sri Lanka, a study that looked
at the incidence of thyroid cancer over 28 years, reported
a signiﬁcant reduction of anaplastic histology [47]. The
incidence of ATC did not change signiﬁcantly in a study
from Scotland [48] .O n ef o rt h ed e c r e a s i n gi n c i d e n c eo f
ATC in these several locations could be that a more accurate
d i a g n o s i si sb e i n gm a d e .
4.RiskFactors
In one study, 25% of the ATC patients had a prior history
of thyroid goiter and another 10% with family history of
goiter [7]. Other studies have reported a similar association
between goiter and ATC [49]. It is also known that ATC is
more common in places with endemic goiter, and thus with
improvements in iodine supplementation, the incidence of
thistumorwouldbeexpectedtodecline.Besicandcolleagues
report in a study from Slovenia that when the iodination of
salt was increased from 10mg of potassium iodide/kg since
1972 to 25mg of potassium iodide/kg between 1997 and
1998 to 2008, the mean incidence of ATC decreased from
6.2 (range, 3–12) between 1972 and 1997 to 4 (range, 2–10)
between 1998 and 2008 [50].
5.Presentation
LocalsymptomsofATCmostcommonlybeginwitharapidly
evolving central neck mass (77%) followed by noticeable
dysphagia (40%), voice change or hoarseness (40%), and
stridor (24%). Regional symptoms included a noticeable
lymph node mass (54%) and neck pain (26%). Systemic
symptoms include anorexia, weight loss, and shortness of
breath with pulmonary metastases. Metastases were found
in 50% of patients at presentation with 25% developing
metastasis during the course of disease. Lungs (80%), bone
(6–16%),and brain (5–13%) were the most common sites of
metastasis [8].
6.Prognosis
In an analysis of survival of ATC patients from the SEER
database from 1983 to 2002, which included patients who
survived for more than a month, the median survival was
4 months. On multivariate analysis, distant or metastatic
disease, tumorsize greater than 7 centimeters, and treatment
with surgery with or without radiotherapy were statistically
signiﬁcant prognostic markers (P ≤ .05). Of interest,
when the authors stratiﬁed patients by the extent of disease
and looked into the beneﬁt of radiotherapy after surgery,
they found that patients with extracapsular extension into
adjacent tissue, the addition of radiotherapy was of beneﬁt.
Radiotherapy after surgery was of no beneﬁt in patients
who had disease conﬁned to the thyroid or had distant
metastasis [51]. Age, sex, size of the tumor, resectability,
and the extent of disease has been shown to aﬀect the
course of the disease [27]. In a SEER-based study in the
United States by multivariate analysis, only age less than
60 years, an intrathyroidal tumor, and the combined use of
surgical and external beam radiation therapy were identiﬁedJournal of Oncology 3
Table 1: Chart review and retrospective studies.
Authors Year Site No. of
pts Study details Results
Swaak-Kragten
et al. [30] 2009 Netherlands 75 Chart Review
1972–2003
When treated with Doxorubicin and radiation, the median
survival was 3 months.1yr OS was 9%. Locoregionalcontrol
was signiﬁcantly higher in patients who had undergone
R0/R1 resection or chemoradiation, with best results for
patients who underwent both (complete remission in 89%).
Vrbic et al. [31] 2009 Serbia 16 Chart Review
1997–2007
Radiation was combined with doxorubicin 60mg/m2 and
cisplatin 40mg/m2 every 3 weeks. Overall response rate was
of 25% (95%CI: 7–55). Mean patient OS was 12.33 months
(95%CI: 9.09–15.56) and median OS 11.0 months (95%CI:
8.56–13.44).
Yau et al. [32] 2008 Hong Kong 50 Chart review
1996–2006
Median survival was 97 days. On univariate analysis,age ≤
65 (P ≤ .01), absence of metastatic disease at presentation
(P<. 01), surgical resection (P<. 01), and postoperative
radiotherapy was associated with longer survival. Cytotoxic
chemotherapy was not associated with longer survival.
Lim et al. [33] 2007 USA 37 Chart review
1984–2006
A median radiation of dose 5760cGy, >4500cGy in 32 (87%)
was administered through hyperfractionated or once-daily
schedules. Median number of treatments received 6, >4i n2 4
(65%). 2-year outcomes: locoregional control 25%;
progression free survival 8%; overall survival 18%. 6 patients
remained alive at the time of last followup with survival
durations of 4, 11, 12, 57, 59, and 141 months,respectively.
Lee et al. [34] 2006 Korea 15 Chart review
1988–2003
The mean overall survival time of the 15 patients was 237
days (range, 28–717 days). The 6, 12, 18, and 24-month
survival rates were 33%, 26%, 13%, and 0%.
Wang et al. [35] 2006 Canada 47 Chart review
1983–2004
The 6-month local progression-free success rate was 95%
(P = .0001) with radical radiotherapy > 40Gy compared to
64% with palliative radiotherapy at <40Gy. Survival was 11
months with radical and 3 months with palliative
(P = .0001). The median overall survival time in patients
with twice-daily fractionation (13 months) was 3 months
longer than patients treated with once-daily fractionation
(10 months), but the diﬀerence was not statistically
signiﬁcant (P = .3).
Veness et al. [36] 2004 Australia 18 Chart review
1979–2002 Median survival was 6.2 months.
Haigh et al. [6] 2001 Canada 33 Chart review
In patients treated with potentially curative resection,
median survival was 43 months and was 3 months with
palliative resection (P = .002). The median survival of 3.3
months with only chemotherapy and irradiation and
palliative resection (P = .63).
McIver et al. [27] 2001 USA 134 Chart review
1949–1999
Extent of resection or completeness of resection did not
aﬀect survival. (P>. 4). Postoperative radiotherapy
improved median survival (5 versus 3 months) but was not
signiﬁcant (P<. 08).
Besic et al. [37] 2001 Slovenia 162 Chart review
1972–1998
82 patients with distant metastasis at presentation were
excluded. Patients were divided into primary surgery
(n = 26) or primary chemotherapy and/or radiation therapy.
One-year survival was similar in both groups (P = .17).
Sugino et al. [38] 2002 Japan 40 Chart review
1989–1999
The one-year survival rate for surgery was 60%. The survival
rate without surgery was 21%. Surgery and chemotherapy
were both used in some patients. One-year survival rates for
patients with small focus of anaplastic thyroid cancer with
well-diﬀerentiated thyroid cancer were 73%.4 Journal of Oncology
Table 1: Continued.
Authors Year Site No. of
pts Study details Results
Heron et al. [39] 2002 USA 32 Chart review
1952–1999
Patients were divided into two groups. Group 1 patients
between 1952–80 (n = 9) and Group 2 between 1981–1999
(n = 23). Group 1 patients received once daily radiation and
Group 2 patients twice-daily radiation with chemotherapy of
doxorubicin, pacitaxel, vincristine, or cisplatin There was a
combination of therapies in both groups, with the above
generalizations.2-year survival was 44% in group 1 and 52%
in group 2. Progression-free survival was 53% group 1 and
38% group 2. The authors concluded that hyperfractionated
radiation with chemotherapy is associated with better
survival but not progression-free survival.
Nilssonet al. [18] 1998 Sweden 81 Chart review
1971–1997
Eight patients (10%) survived more than 2 years and were
treated with combinations of chemotherapy, radiotherapy,
and surgery.
Tennevall et al. [40] 1994 Sweden 33 Chart review
1984–1992
Combination of hyperfractionated radiotherapy,
doxorubicin, and debulking surgery. Preoperative radiation
up to 30Gy and post operative radiation up to 46Gy. 20mg
doxorubicin per week. 48% had no local recurrence and,
24% died due to local failure. In 4 patients survival exceeded
2yrs. Local control better with accelerated radiation therapy.
Venkatesh et al. [24] 1990 USA 121 Chart review Median survival was 7.2 ±10 months. 35% patients had
well-diﬀerentiated thyroid cancer as well.
Junor et al. [10] 1992 UK 91 Chart review
1961–1986
Surgery and radiation were used. Total or partial
thyroidectomy increased survival. 80% responded to
radiation therapy.
Levendag et al. [41] 1993 Holland 51 Chart review
1970–1986
Local control achieved a median survival of 7.5 months and
local residual disease 1.6 months.
Kim and Leeper [12] 1987 USA 41 Chart review
1979–1986
Only reporting Group 2 with anaplastic thyroid cancer.
Weekly doxorubicin 10mg/m2 prior to hyperfractionated
radiotherapy with 160cGy twice daily to total 57–60cGy in
40 days. Initial complete remission rate was 84%. Local
tumor control at 2 years was 68% with combined therapy.
Median survival was 1 year.
as independent predictors of lower cause-speciﬁc mortality
[52] .I no t h e rs e r i e s ,f e m a l es e x ,t u m o rs i z el e s st h a n6
centimeters, age, and the extent of disease were the most
favorable prognostic markers [23, 53]. Among Koreans
less than 60 years of age, tumor size less than 7cm, and
lesser disease burden were independent predictors of lower
mortality [54]. A recent study from France based on 26
patients with ATC, univariate analysis showed that age above
75,capsularinvasion,lymphnodesmetastasis, tumorresidue
after surgery, and lack of multimodal treatment (particularly
radiotherapy in patients without tumor residue) are poor
prognosistic factors. Multivariate analysis in the same cohort
showed age above 75, followed by node invasion, capsular
invasion, and female sex to be poor prognosticators [55]. In
a study by Venkatesh and colleagues, patients with localized
disease had a median survival of 8 months in comparison
to 3 months for patients with metastatic disease [24]. A
prognostic index was developed by Sugitani and colleagues
from a review of their series of 47 patients over 33 years [56].
Their index was based on a combination of four risk factors:
(1)presenceofacutesymptoms,(2)tumorsizegreaterthan5
centimeters,(3)distantmetastasis, and(4)whitecellcount ≥
10,000/μL[ 56]. Patients with a prognostic index less than or
equal to one had a 62% survival rate at 6 months, whereas all
patients with prognostic index of three and four died within
six and three months, respectively.
7.GeneralTherapeuticApproach
Patients with ATC even in the absence of metastatic disease
a r ec o n s i d e r e dt oh a v es y s t e m i cd i s e a s ea tt h et i m eo fd i a g -
nosis. All ATCs are considered stage IV by the International
UnionAgainstCancer(UICC)—TNMstagingandAmerican
Joint Commission on Cancer (AJCC) system. Multimodality
treatment consisting of surgery when feasible combined
withradiationandchemotherapyisgenerallyrecommended.
The surgery must not compromise the functional anatomy
of the cervical structures. The most common cause of
death is invasion of vital local structures in the neck.
Consequently, achieving good local control with surgery
and or radiation confers short term palliative and survival
beneﬁt.Radiotherapyaloneandincombinationwithsurgery
has been shown to achieve good local control in manyJournal of Oncology 5
studies. There is no consensus on the sequence of radiation
and surgery. A summary of retrospective and prospective
studies with the most important results are presented in
Tables 1 and 2, respectively.
8.Radiation
Radiation does not alter the course of ATC in most patients.
On the other hand, when combined with surgery and
chemotherapy, it can prolong the short-term survival in
select and subset of patients. Intensity-modulated radiation
therapy (IMRT) based on computerized treatment planning
and delivery is able to generate a dose distribution that
deliversradiation accurately with sparing of the surrounding
normal tissue [57, 58]. Higher doses of radiation can be
given over a shorter time with less toxicity by employing
hyperfractionation techniques [59, 60]. Toxicity can be a
limiting factor with radiation. Kim and Leeper reported
complications particularly, pharyngoesophagitis and tra-
cheitis in their series [12]. Wong and coworkers also noted
skin changes, esophageal toxicity, and radiation myelopathy
[59]. Daily doses of greater than 3Gy should be cautiously
used as it can increase the incidence of myelopathy [59].
A report from MD Anderson Cancer Center compared
outcomes for ATC patients treated with conformal 3-
dimensional radiotherapy (3DRT) or IMRT. Of the 53 con-
secutive patients were analyzed, 31 patients were irradiated
with curative intent with a median radiation dose of 55 Gray
(Gy; range, 4–70Gy). Thirteen patients received IMRT to a
median60Gy(range,39.9–69.0Gy).Themajorityofpatients
received chemotherapy with radiation The Kaplan-Meier
estimate of overall survival (OS) at 1 year for deﬁnitively
irradiated patients was 29%. Five patients without distant
metastases had no evidence of disease at last followup.
Use of IMRT versus 3DRT did not inﬂuence toxicity [71].
Hyperfractionated radiation regimens delivering a total of
around46Gyhavebeenmosteﬀectivebothwithandwithout
doxorubicin [12, 40, 72]. Wong and coworkers also noted
skin changes, esophageal toxicity, and radiation myelopathy
[59].
9.Chemotherapy
Ithasbeenfoundthatinvitro,anaplasticcelllinesexpressless
multiple drug resistance (mdr1) mRNA and P-glycoprotein
while expressing more multidrug resistance–associated pro-
tein(MRP)[73,74].Thiscouldexplainthealmostuniformly
poor outcomes with chemotherapy. Doxorubicin is the
most common agent used. A literature review by Ahuja
showed a response rate around 22% for doxorubicin [75].
Swaak-Kragten and others did a retrospective analysis of
seventy-ﬁve ATC-patients treated between 1972 and 2003
in the Netherlands. Thirty-six patients underwent up-front
surgery of which with 53% had a R0(negative microscopic
resection margin)/R1(positive microscopic resection mar-
gin) resection. Prior to 1988, adjuvant treatment consisted
of conventional radiotherapy (RT) and/or chemotherapy
(CT). After 1988, 30 eligible patients were enrolled in
a protocol consisting of locoregional radiotherapy in 46
fractionsof1.1Gy,giventwicedaily,followedbyprophylactic
irradiation of the lungs (PLI) in 5 daily fractions of
1.5Gy. During radiation, low-dose doxorubicin (15mg/m2)
was administered weekly followed by adjuvant doxorubicin
(50mg/m2) 3-weekly up to a cumulative dose of 550mg/m2.
Twenty-ﬁve ineligible patients were treated conventionally.
The overall median survival was 3 months, 1-year OS 9%.
Locoregionalcontrolwassigniﬁcantlyhigherinpatientswho
had undergone R0/R1 resection or chemoradiation, with
best results for patients who underwent both (complete
remission in 89%). However, the survival beneﬁt of patients
who reached CRremained borderline (median OS7months,
1-year OS 32%). The three patients who survived for more
than 5 years had undergone R0/R1 surgical resection and
chemoradiation. Acute toxicity in the protocol group was
signiﬁcantly higher than that in the nonprotocol group,
with 46% versus 11% grade 3 pharyngeal and/or esophageal
toxicity [30].
In a study from Serbia, between 1997 and 2007, 16
inoperable patients were treated with radiotherapy at 60Gy
followed by doxorubicin 60mg/m2 and cisplatin 40 mg/m2
every 3 weeks. The overall response rate (ORR) was 25%
(95% CI: 7–55). No toxic deaths occurred or grade 4 adverse
events were reported after radiotherapy. Grade 4 toxicity was
seen in 3 patients after chemotherapy. Mean patient OS was
12.33 months (95%CI: 9.09–15.56) and median OS 11.0
months (95%CI: 8.56–13.44)[31]. Shimaoka and colleagues
reported three complete and three partial responders out
of 19 patients treated with doxorubicin and cisplatin [76].
Valproic acid, a histone deacetylase inhibitor, enhanced the
eﬀect of doxorubicin on anaplastic thyroid cancer cell lines
in a preclinical study [77].
Paclitaxel was found to have a response rate of53% (95%
conﬁdence interval: 29–76%) with one complete response
and nine partial responses in 19 evaluable patients in a
study conducted by Ain and colleagues [69]. A nonconven-
tional response rate deﬁnition was utilized in this study. A
recent study done in Japan compared overall survival after
inductionchemotherapy by weekly paclitaxeladministration
for patients with stage IVB (nine patients) and IVC (four
patients) disease with that of ATC patients with stage IVB
(n = 50) and IVC (n = 13) treated without paclitaxel.
Complete response was seen in one, and two demonstrated
partial response in the stage IVB group and one patient
showedPRinstageIVC.Afterpaclitaxel,curativesurgeryand
adjuvant therapy were performed forfourpatientswith stage
IVB. All four patients were reported to be alive and disease-
free 32 months after treatment. All four patients with stage
IVC died of carcinoma within 8 months. Overall survival of
stage IVB patients with induction chemotherapy was better
(P = .0213) than that without the chemotherapy and also
better (P = .0467) than those with chemotherapy other
than paclitaxel. However, induction chemotherapy did not
improvetheoverallsurvivalofstageIVCpatients(P = .2002)
[78]. Docetaxel was administered intravenously at a dose
of 60mg/m2 over the course of 1h every 3 weeks in seven
patients with ATC who had received no prior chemotherapy
in recent single center study in Japan. One patient had
complete response, two patients had stable disease, and four6 Journal of Oncology
Table 2: Prospective studies.
Author Year Site No. of
pts Study details Results
Sosa
et al. [61] 2010 International 80
55pts were randomized to
paclitaxel/carboplatin and fosbretabulin,
and 25 patients were randomized to receive
paclitaxel and carboplatin only. Pts were
followed until they died.
Fosbretabulin was well tolerated with
carboplatin and paclitaxel. Improved overall
survival (OS) in ATC from 4.1 months to 5.1
months.OS was longer in younger patients
<60yrs increasing from medial of 3.1
months to 10.9 months (HR: 0.38, 95%CI:
0.16, 0.88, P = .0222).
Troch
et al. [62] 2010 Austria 6
Standard external beam radiation of 60gy
was combined along with docetaxel at
100mg ﬁxed dose every 3wks for a total of
six cycles starting within the ﬁrst week of
radiation.
One patient had only completed radiation at
the time of the report. Four patients
achieved complete remission,and two
achieved partial response. After a median
followup of 21.5 months (range, 2–40
months),ﬁve patients were alive.
Mooney
et al. [63] 2009 USA 26 26 patients with biopsy-proven ATC
received fosbretabulin at 45mg/m2.
There was no objective response. Median
survival was 4.7 months with 34% and 23%
alive at 6 and 12 months,respectively.
Median duration of stable disease in seven
patients was 12.3 months (range, 4.4–37.9
months).Lower baseline sICAM-1 levels
correlated with better event-free survival.
Fosbretabulin was well tolerated with grade
3 toxicity in 34% and grade 4 in 4% of
patients.
Nagaiah
et al. [64] 2009 USA 16
Patients with biopsy-proven ATC who had
progressed on cytotoxic chemotherapy with
or without radiation were treated with
sorafenib 400mg BID on a 28 day cycle.
2 of the 15 evaluable patients (13%) had
partial response, and 4 patients (27%) had
stable disease. Median time in study was 2
months.Median duration of PD/SD was 5.1
months,and median duration of survival
was 3.5 months.
Koussis
et al. [65] 2006 Italy 56
Patients were divided into 3 groups. Group
A: 19 patients radiotherapy, total
thyroidectomy, and chemotherapy. Cisplatin
once a week and by radiation at 36Gy in 18
fractions over 3 weeks, followed by total
thyroidectomy and by further chemotherapy
with doxorubicin and bleomycin.
Additionally, ﬁve patients received weekly
docetaxel. Group B: consisted of 19 patients
with distant metastasis at diagnosis who
received chemotherapy (Platinum-based
combination).Group C: consisted of 18
elderly patients in poor general condition; 6
received local radiation, while 12 did not
receive any treatment.
Five complete responses were seen in
patients from Group A. Four patients had
long-term survival (14, 15, 24, and 41
months) with a disease-free survival interval
of 6, 8, 11, and 32 months. Median survival
rates for Groups A, B, and C was 12, 5.7, and
4 months,respectively.
Wallin
et al. [66] 2004 Sweden 22
Hyperfractionated radiotherapy 1.6Gy × 2
to a total target dose of 46Gy given
preoperatively, 20mg doxorubicin was
administered intravenously once weekly and
surgery was carried out 2-3 weeks after the
radiotherapy.
17 of these 22 patients were operated. Partial
regression in 7 others; the one patient whose
tumor failed to respond was treated only
once daily. Two patients died of spinal cord
necrosis and a third of pneumonitis due to
the unexpected increase in radiation toxicity
caused by the concurrent administration of
doxorubicin. None of these 17 patients got a
local recurrence. No survival data.
De Crevoisier
et al. [67] 2004 France 30
Hyperfractionated accelerated radiotherapy
and total of 6 cycles of doxorubicin/cisplatin
was used.
Complete local response was seen in 19
patients. Overall survival at 3 years was 27%
and median survival was 10 months.Death
was related to local progression in 5% of
patients.Journal of Oncology 7
Table 2: Continued.
Author Year Site No. of
pts Study details Results
Mitchell
et al. [68] 2002 USA 28
28 patients with ATC without distant
metastases received radiotherapy to the
primary tumor and bilateral neck in 1.6Gy
fractions twice daily and 3 days per week,
with concurrent doxorubicin 10mg/m2
weekly. Three histological subsets: anaplastic
carcinoma with giant and/or spindle cell
features (n = 12); anaplastic carcinoma
arising from papillary or follicular
carcinoma (n = 8); and undiﬀerentiated
(n = 8).
The 3-year actuarial local control,
metastasis-free survival, and overall survival
rates were 47%, 8%, and 14%, respectively.
Followup amongthe ﬁve currently living
patients is 82, 27, 4, 3, and 1 months,
respectively. Site of ﬁrst failure was distant
in 13 patients and local in 7 patients.
Ain
et al. [69] 2000 USA 20
Patients received 96-hour continuous
infusion of paclitaxel every 3 weeks for 1 to
6 cycles; the ﬁrst 7 patients received
120mg/m2 per 96 hours, and the rest
received 140mg/m2 per 96 hours.
Of the 19 evaluable patients, there was a
53% total response rate (95% conﬁdence
interval; 29–76%) including 1 complete
response and 9 partial responses (including
one oﬀ protocol). Nonconventional
response criteria.
Busnardo
et al. [70] 2000 Italy 39
A total of 16 patients (Group 1) were treated
with total thyroidectomy, radiation therapy,
and chemotherapy in various orders. Nine
patients with distant metastases at diagnosis
(Group 2) received chemotherapy; one
patient had disappearance of lung
metastases and was then treated by total
thyroidectomy and further chemotherapy.
Group 3 consisted of 14 elderly patients in
poor general conditions; 4 of these received
local radiation therapy, while the remaining
did not receive any treatment.
Median survival rate was 11 month for
Group 1. It was 5.7 months for Group 2, and
4 months for Group 3. Multimodality
treatment was associated with increased
survival. Nine out of 16 patients, who
underwent surgery and complementary
treatment, had no local progression.
Mitchel
et al. [16] 1999 UK 17
Twice-daily radiation for 5 days a week to a
total dose of 60.8Gy in 32 fractions over
20–24 days was given in two or three phases.
Three patients with ATC demonstrated a
complete clinical response, and 7 patients
achieved a partial response. Five patients
had stable disease, and 2 patients died before
radiotherapy was completed.
Schlumberger
et al. [19] 1991 France 20
Chemotherapy and radiation for patients
aging less than 65 years treated with
doxorubicin and cisplatin; patients older
than 65 years with mitoxantrone and
radiation at 17.5Gy.
Three patients survived more than 20
months; 5 patients had complete local
tumor response.
Tennevall
et al. [60] 1990 Sweden 16
Hyperfractionated radiotherapy,
doxorubicin, and debulking surgery. The
radiotherapy was preoperatively
administered to a target dose of 30Gy in 3
weeks, and postoperatively to an additional
dose of 16Gy in 1.5 weeks. 20mg
doxorubicin was used.
Five patients achieved local complete
remission,and 3 patients were alive
disease-free at 10, 30, and 30 months,
respectively, after diagnosis. Only 6 patients
succumbed to local failure.
Kim and
Leeper [12] 1987 USA 19
Group 2 patients with anaplastic giant and
s p i n d l ec e l lc a r c i n o m ao ft h et h y r o i d
(n = 19) received doxorubicin (10mg/m2)
before hyperfractionated radiation.
Radiation therapy was carried out with a
fractional dose of 160cGy per treatment
twice a day for 3 days per week to a total
dose of 5760cGy in 40 days.
Local tumor control rates at 2 years after
combined therapy were 77% and 68%,
respectively. The median survival time was 4
years for group 1 and 1 year for group 2.8 Journal of Oncology
patients had progressive disease. The response rate was 14%,
and the disease control rate (complete/partial response plus
stable disease) was 43%. The median time to progression
was 6 weeks (range, 1–50). The authors report that the
toxicity was tolerable [79]. In a small prospective study of
6 patients from Austria, standard external beam radiation
of 60gy was combined along with docetaxel at 100mg ﬁxed
dose every 3weeks for a total of six cycles starting within
the ﬁrst week of radiation. One patient had only completed
radiation at the time of the report. Four patients achieved
complete remission and two partial response. After a median
followup of 21.5 months (range, 2–40 months), ﬁve patients
were alive [62]. Paclitaxel when combined with manumycin
showed the most response in combination when compared
to either of the agents alone in anaplastic thyroid cancer cell
lines in nude mouse [80]. In preclinical studies paclitaxel,
gemcitabine, and vinorelbine have showed activity against
ATC cell lines [81].
Chemotherapies with bleomycin, etoposide, cisplatin,
and methotrexate have poor response rates with no long-
term survival [9, 65]. Other combinations with vincristine
and melphalan have not produced any improvements in the
rate of responders [75, 82].
10.EmergingTherapies
As more data becomes available regarding the molecular
pathogenesis of ATC, more targeted therapies are appearing
in the clinic. Two of the most promising class of agents are
the small-molecule tyrosine-kinase angiogenesis inhibitors
andvasculardisruptingagents.Therearetwosmall-molecule
tyrosine-kinase inhibitors in the midst of Phase II clinical
trials including imatinib mesylate (Gleevac, Novartis, East
Hanover, NJ, USA) and sorafenib (Nexavar, Onyx, San Fran-
sisco, Calif, USA). Imatinib mesylate is an orally available
selective c-abl tyrosine-kinase inhibitor. It has been shown
eﬀective in vitro in anaplastic thyroid cell lines [93, 94].
Another study did not ﬁnd it eﬀective [95]. Sorafenib is a
novel small-molecule tyrosine-kinase inhibitor which acts
on the raf-1 serene/threonine kinase. BRAF mutations are
thought to be an important event in the evolution of
ATC and are a potential therapeutic target for treatment.
Sorafenib also blocks the receptor tyrosine kinases to the
vascular endothelial growth factor receptor 2 (VEGFR2)
and platelet-derived growth factor receptor β (PDGFR-β)
and thus has antiangiogenesis properties as well. Sorafenib
inhibited the growth of rat orthotopic ATC xenografts, and
thesurvivaloftestanimalswasimprovedinrecentlyreported
preclinical study [96]. This agent was studied in a clinical
trial by Gupta-Abramson and colleagues in patients with
advanced thyroid cancer, regardless of histology. Two of
the 30 patients studied had anaplastic thyroid cancer. Both
patients progressed despite therapy. However, one patient
had a 50% decrease in size of a shoulder nodule at 4 weeks
of treatment, before progressing with pericardial nodules at
7 weeks [97]. Sorafenib, at 400mg bid on a 28 day cycle, was
used on 16 patients with ATC, who had failed chemotherapy
and/or radiotherapy. Median age was 55 years, two of the 15
(13%) evaluable patients had partial response, and 4 (23%)
had stable disease. Median time in study was 2 months.
Median duration of PD/SD was 5.1 months, and median
duration of survival was 3.5 months. This study is ongoing
at this time [64].
Axitinib (AG-013736) is an oral, selective inhibitor of
VEGFRs 1, 2, and 3, and preclinical studies show that it
blocks angiogenesis and tumor blood ﬂow in preclinical
models [98]. Cohen and colleagues studied this agent in a
clinicaltrialonpatientswithadvancedthyroidcancer.Twoof
the 60 patients had ATC. One patient has a partial response,
and the other one progressed in spite of treatment [99].
Fosbretabulin is a derived from the African bush willow,
Combretum caﬀrum. It is a novel tubulin-binding, vascu-
lar=disrupting agent and should be diﬀerentiated from the
angiogenesis inhibitors discussed above. It displays potent
and selective toxicity towards tumor vasculature and is
thoughttoactbyendothelialdisruptionofestablishedtumor
vasculature [100, 101]. The agent binds avidly to tubulin at
the colchicine-binding site to inhibit microtubule assembly
and destabilizes the cytoskeleton [102]. Fosbretabulin has
also been shown to enhance or act synergistically with
radiation and several chemotherapeutic agents [103, 104].
In a Phase II study in 26 patients with ATC, this agent was
found to be well tolerated with grade 3 or greater toxicity
being observed in 35% of patients. Median survival was
4.7 months, with 34% and 23% alive at 6 and 12 months,
respectively. Median duration of stable disease was 12.3
months (range 4.4–37.9). Low-baseline soluble intracellular
adhesion molecule-1 (sICAM) appeared to predict better
event-free survival [63]. In a Phase 2/3 trial, fosbretabulin,
paclitaxel, and carboplatin combination was compared to
carboplatin and paclitaxel only in 80 patients with ATC.
Interim results have been presented at the European Society
ofMedicalOncologymeeting inMilan, Italy(October2010).
Preliminary results showed that the combination is well
tolerated and showed an improvement in overall survival
from 4.1 months to 5.1 months, with hazard ration of
0.71. P value could not be calculated, as the study had
to be truncated due to poor accrual. One-year survival
was almost doubled with fosbretabulin, when compared to
chemotherapy alone (23% versus 9%). OS was objectively
longer in patients less than 60 years of age, increasing from
a median of3.1 months to 10.9 months (HR of0.38, 95%CI:
0.16, 0.88) [61].
In a pilot study, two patients with ATC had intra-
tumor injection of retroviral vector with the human IL-2
gene and the suicide gene thymidine kinase of HSV type
2. Gene therapy resulted in marked increase in T-helper-
type 1 cytokine proﬁle and induced radiologically proven
necrosis in the tumor [105]. Sodium stibogluconate is a
trivalent antimonial compound, traditionally used for the
treatment of leishmaniasis. It has recently been shown as
an inhibitor of selective protein tyrosine phosphatases and
could augment immune system activation when combined
with interferon alfa-2b [106]. The MMP-activated anthrax
lethal toxin (LeTx) was shown to inhibit orthotopic ATC
xenograft progression in both toxin-sensitive and toxin-
resistant ATC cells via reduced endothelial cell recruitmentJournal of Oncology 9
Table 3: Preclinical agents.
Mechanism Agents Studies
Loss of p53 or abnormalp53 is expressed in
anaplastic thyroid cancer [83]
Adenovirus with wild
type p53
Blagosklonnyet al. showed that anaplastic thyroid
cancer cell lines infected with the p53 adenovirus
became more sensitive to doxorubicin.
Unknown [84] Bovine seminal
ribonuclease In vivo tumor regression of anaplastic thyroid cancer.
Inhibition of cyclin-dependent kinase activity
[85]
Bone morphogenic
protein Inhibition of 4 of 6 anaplastic thyroid cancer cell lines.
EGFR Tyrosine-kinase inhibitor [86] ZD1839 (geﬁtinib)
EGFR is overexpressed in anaplastic thyroid cancer in
vitro/vivo and geﬁtinib induces apoptosis in vitro and
inhibits subcutaneous mouse models of anaplastic
thyroid cancer.
EGFR Monoclonalantibody [87]C e t u x i m a b
As single agent cetuximab had no activity, but with
irinotecan it inhibited orthotopic anaplastic thyroid
cancer xenografts more than doxorubicin.
EGRF/VEGF Receptor blocker [88] AEE788 In vitro inhibition and nude-mouse inhibition with
pacitaxel.
Histone Deacetylase Inhibitors [77, 89–91] Valproic acid and
other novel agents
Restored radio iodide uptake and restoration of p53 or
pseudo- p53 activity.
Inhibition of gelatinase class of matrix
metalloproteinases (MMP) that are activated in
ATC [92]
MMP-activated LeTx Reduced endothelial cell recruitment and subsequent
tumor vascularization
and subsequent tumor vascularization [92]. Other agents
that have been reported to be eﬀective in vitro studies
include replication-competent vaccinia virus (GLV-1h68)
[107]. Agents that are in the midst of preclinical evaluation
are listed in Table 3.
11.Summaryand Conclusions
The overall prognosis of ATC continues to be poor, with the
5-year survival in recent SEER database study to increase
the order of 5.6% to 11.4% among all regions of the United
States [108]. There has not been much improvement in
response rates achieved above the 20% response rate seen
with doxorubicin over the years. Further research is needed
to evaluate new treatments for this almost uniformly fatal
disease.
Abbreviations
ATC: Anaplastic thyroid cancer
CA4P: Combretastatin A4 phosphate, also known as
fosbretabulin.
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